Suppression of c-Myc enhances p21WAF1/CIP1 -mediated G1 cell cycle arrest through the modulation of ERK phosphorylation by ascochlorin. 2018

Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
Research Institute of Biomedical Engineering and Department of Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.

Numerous anti-cancer agents inhibit cell cycle progression via a p53-dependent mechanism; however, other genes such as the proto-oncogene c-Myc are promising targets for anticancer therapy. In the present study, we provide evidence that ascochlorin, an isoprenoid antibiotic, is a non-toxic anti-cancer agent that induces G1 cell cycle arrest and p21WAF1/CIP1 expression by downregulating of c-Myc protein expression. Ascochlorin promoted the G1 arrest, upregulated p53 and p21WAF1/CIP1 , and downregulated c-Myc in HCT116 cells. In p53-deficient cells, ascochlorin enhanced the expression of G1 arrest-related genes except p53. Small interfering RNA (siRNA) mediated c-Myc silencing indicated that the transcriptional repression of c-Myc was related to ascochlorin-mediated modulation of p21WAF1/CIP1 expression. Ascochlorin suppressed the stabilization of the c-Myc protein by inhibiting ERK and P70S6K/4EBP1 phosphorylation, whereas it had no effect on c-Myc degradation mediated by PI3K/Akt/GSK3β. The ERK inhibitor PD98059 and siRNA-mediated ERK silencing induced G1 arrest and p21WAF1/CIP1 expression by downregulating c-Myc in p53-deficient cells. These results indicated that ascochlorin-induced G1 arrest is associated with the repression of ERK phosphorylation and c-Myc expression. Thus, we reveal a role for ascochlorin in inhibiting tumor growth via G1 arrest, and identify a novel regulatory mechanism for ERK/c-Myc.

UI MeSH Term Description Entries
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000475 Alkenes Unsaturated hydrocarbons of the type Cn-H2n, indicated by the suffix -ene. (Grant & Hackh's Chemical Dictionary, 5th ed, p408) Alkene,Olefin,Olefins,Pentene,Pentenes
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016271 Proto-Oncogene Proteins c-myc Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis. L-myc Proteins,N-myc Proteins,c-myc Proteins,myc Proto-Oncogene Proteins,p62(c-myc),Proto-Oncogene Products c-myc,Proto-Oncogene Proteins myc,myc Proto-Oncogene Product p62,p62 c-myc,L myc Proteins,N myc Proteins,Proteins myc, Proto-Oncogene,Proto Oncogene Products c myc,Proto Oncogene Proteins c myc,Proto Oncogene Proteins myc,Proto-Oncogene Proteins, myc,c myc Proteins,myc Proto Oncogene Product p62,myc Proto Oncogene Proteins,myc, Proto-Oncogene Proteins,p62 c myc

Related Publications

Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
June 2005, Molecular and cellular biology,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
July 2010, Molecular cancer therapeutics,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
October 1995, Oncogene,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
July 2003, Cancer research,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
September 1990, FEBS letters,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
October 2014, Anticancer research,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
November 2005, Biochimica et biophysica acta,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
October 1998, Oncogene,
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
January 2019, Medicina (Kaunas, Lithuania),
Yun-Jeong Jeong, and Hyang-Sook Hoe, and Hyun-Ji Cho, and Kwan-Kyu Park, and Dae-Dong Kim, and Cheorl-Ho Kim, and Junji Magae, and Dong Wook Kang, and Sang-Rae Lee, and Young-Chae Chang
September 2008, Carcinogenesis,
Copied contents to your clipboard!